Evidence map›Paper›PMID 41366533›Full record

ArticleLeukemia2026

Late toxicity and long-term efficacy of first-line bendamustine and rituximab combination in patients with Waldenström macroglobulinemia.

Véronique Leblond, Jean-Richard Eveillard, Driss Chaoui, Doriane Cavalieri, Caroline Dartigeas, Lise Willems, Ronan Le Calloch, Fathia Merabet, Xavier Roussel, Benoît Bareau and 5 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Leukemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Véronique LeblondHematology Department, APHP, Sorbonne University, Hospital La Pitié Salpêtrière-Charles Foix, Paris, France. veronique.leblond@aphp.fr.ORCID http://orcid.org/0000-0001-9974-8868
Jean-Richard EveillardHematology department Brest University Hospital, Brest, France.
Driss ChaouiHematology Department, Argenteuil Hospital, Argenteuil, France.
Doriane CavalieriHematology Department, Lille Regional and University Hospital, Lille, France.
Caroline DartigeasHematology Department Bretonneau Regional and University Hospital, Tours, France.
Lise WillemsHematology Clinic, Cochin University Hospital, APHP, Paris, France.
Ronan Le CallochHematology Clinic, Cornouaille Hospital Center, Quimper, France.
Fathia MerabetHematology and Oncology Clinic, André Mignot Hospital, Versailles, France.
Xavier RousselHematology Department, University of Franche-Comté, INSERM UMR 1098, Besançon University Hospital, Besançon, France.
Benoît BareauHematology and Internal Medicine Clinic, Sévigné Vivalto Santé Private Hospital, Cesson-Sévigné, France.
Sabine TricotHematology Clinic, Valenciennes Hospital, Valenciennes, France.
Jehan DupuisLymphoid Malignancies Unit, APHP, Henri Mondor-Albert Chennevier Hospital, Créteil, France.
Stéphanie PoulainCellular Hematology, Biology and Pathology Center, Lille Regional and University Hospital and INSERM UMR 1172, IRCL, Lille, France.
Kamel LaribiHematology Department, Le Mans Hospital, Le Mans, France.
Damien Roos-WeilHematology Department, APHP, Sorbonne University, Hospital La Pitié Salpêtrière-Charles Foix, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41366533

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.